Expanding the range of bioconjugate vaccines to fight more bacterial threats Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. We are expanding the range of bacterial targets that can be addressed with bioconjugate vaccines. Bioconjugation relies on single cells that simultaneously produce a polysaccharide